Aldeyra Therapeutics Inc. (NASDAQ: ALDX) is 50.29% higher on its value in year-to-date trading and has touched a low of $1.48 and a high of $8.70 in the current 52-week trading range. The ALDX stock was last observed hovering at around $8.47 in the last trading session, with the day’s gains setting it 1.84% off its average median price target of $26.50 for the next 12 months. It is also 67.78% off the consensus price target high of $32.00 offered by 8 analysts, but current levels are 31.27% higher than the price target low of $15.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Currently trading at $10.31, the stock is 43.31% and 48.52% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.44 million and changing 21.72% at the moment leaves the stock 81.96% off its SMA200. ALDX registered 65.49% gain for a year compared to 6-month gain of 113.90%. The firm has a 50-day simple moving average (SMA 50) of $7.20 and a 200-day simple moving average (SMA200) of $6.69.
The stock witnessed a 42.01% loss in the last 1 month and extending the period to 3 months gives it a 46.87%, and is 50.29% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 12.43% over the week and 7.76% over the month.
Distance from 52-week low is 596.62% and 18.51% from its 52-week high.
Aldeyra Therapeutics Inc. (ALDX) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Aldeyra Therapeutics Inc. (ALDX) is a “Buy”. 8 analysts offering their recommendations for the stock have an average rating of 1.50, where 0 rate it as a Hold and 0 think it is a “Overweight”. 8 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Aldeyra Therapeutics Inc. is expected to release its quarterly report on 05/18/2021 and quarterly earnings per share for the current quarter are estimated at -$0.29.The EPS is expected to shrink by -25.10% this year.
Aldeyra Therapeutics Inc. (ALDX) Top Institutional Holders
101 institutions hold shares in Aldeyra Therapeutics Inc. (ALDX), with 883.16k shares held by insiders accounting for 2.28% while institutional investors hold 68.92% of the company’s shares. The shares outstanding are 37.80M, and float is at 31.65M with Short Float at 4.70%. Institutions hold 67.35% of the Float.
The top institutional shareholder in the company is Perceptive Advisors Llc with over 6.29 million shares valued at $46.58 million. The investor’s holdings represent 16.19% of the ALDX Shares outstanding. As of Sep 29, 2020, the second largest holder is Vanguard Group, Inc. (The) with 1.65 million shares valued at $12.24 million to account for 4.25% of the shares outstanding. The other top investors are Acuta Capital Partners LLC which holds 1.65 million shares representing 4.24% and valued at over $12.2 million, while Avidity Partners Management, LP holds 3.68% of the shares totaling 1.43 million with a market value of $10.6 million.
Aldeyra Therapeutics Inc. (ALDX) Insider Activity
A total of 0 insider transactions have happened at Aldeyra Therapeutics Inc. (ALDX) in the last six months, with sales accounting for 0 and purchases happening 0 times. The most recent transaction is an insider purchase by PERCEPTIVE ADVISORS LLC, the company’s 10% Owner. SEC filings show that PERCEPTIVE ADVISORS LLC bought 3,200,000 shares of the company’s common stock on Jul 09 at a price of $4.25 per share for a total of $13.6 million. Following the purchase, the insider now owns 6.29 million shares.
Aldeyra Therapeutics Inc. disclosed in a document filed with the SEC on Mar 16 that DOUGLAS RICHARD (Director) bought a total of 40,000 shares of the company’s common stock. The trade occurred on Mar 16 and was made at $2.75 per share for $0.11 million. Following the transaction, the insider now directly holds 0.13 million shares of the ALDX stock.
Aldeyra Therapeutics Inc. (ALDX): Who are the competitors?
The company’s main competitors (and peers) include Five Prime Therapeutics Inc. (FPRX) that is 220.91% higher over the past 12 months. Regeneron Pharmaceuticals Inc. (REGN) is 30.06% up on the 1-year trading charts. Short interest in the company’s stock has fallen -7.38% from the last report on Nov 12, 2020 to stand at a total of 1.6 million short shares sold with a short interest ratio of 4.51.